retatrutide phase 2 obesity trial The data just dropped — and is rewriting what's possible in medicine Lilly's retatrutide shows 28% weight

58 GLP-1RAs potentially may reduce the risk of AF onset and progression through direct and indirect effects on atrial remodelling, including a reduction in systemic inflammation, improvement of cardiomyocyte metabolism, autonomic nervous system modulation, regulation of intracellular Ca 2+ levels and prevention and possibly reversion of atrial fibrosis

[PMID: 23045054] PubMed record related to this compound for laboratory literature review

2010 Jun 30

He said UKA was keen to centralise its records and now handles all of Farah's medical care

PLoS ONE 7 , e30312

The molecular mechanisms of the relationship between insulin resistance and Parkinsons disease pathogenesis